4 coronavirus treatments, including remdesivir, hydroxychloroquine, flop in large WHO study

October 16, 2020 at 17:04

Four coronavirus drugs were found to have "little or no effect" on hospitalized patients, according to preliminary results from a World Health Organization study.
Anticipated findings from the WHO’s multi-country Solidarity trial were posted ahead of peer review in medRxiv on Thursday, which assessed remdesivir, hydroxychloroquine, interferon and an HIV-drug combo lopinavir-ritonavir.
“The main outcomes of mortality, initiation of ventilation and hospitalization duration were not clearly reduced by any study drug,” according to the study.
CLICK HERE FOR FULL CORONAVIRUS COVERAGEWhile hydroxychloroquine and lopinavir were dropped from the WHO trial over the summer over futility, the remdesivir findings directly contrast with results from a U.S. NIH-led study, which showed to shorten patients' path to recovery by about four to five days.
"The emerging data appear inconsistent with more robust evidence from multiple randomized, controlled studies published in peer-reviewed journals validating the clinical benefit of Veklury® (remdesivir)," company officials wrote.
"We are concerned that the data from this openlabel global trial have not undergone the rigorous review required to allow for constructive scientific discussion, particularly given the limitations of the trial design."
Gilead previously ran its own clinical trials on the drug, and found that 65% of moderately ill patients had improvement after 11 days.
The WHO study involved over 11,000 adults across 405 hospitals in 30 countries on multiple treatments tested against a control arm; 2,750 patients were allocated remdesivir.
(The NIH study involved 1,062 patients who were randomly assigned remdesivir or a placebo for 10 days.)
In the company statement sent to Fox News, Gilead pointed to the WHO trial's "significant heterogeneity in trial adoption, implementation, controls and patient populations" because the trial design prioritized broad access.
She said, in approaching the trials for COVID-19, investigators knew how to write protocols quickly, ideas were shared around the clock and drug manufacturers came forward to donate drugs.
CLICK HERE FOR THE FOX NEWS APP
Source